Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Vivo Capital Information
Geographic Data
Address: 575 High St Ste 201
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
2,761,045Website Global Rank
6,244Website Monthly Traffic
Twitter Followers
Description
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Contact Phone:
+16506880818
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2020 | dMed | Series C | 100M |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 8/2022 | Klavi | Series A | 15M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 8/2018 | TOT BIOPHARM | Series B | 102M |
| 12/2020 | Provivi | Series C | 0 |
| 1/2019 | Innocare | Private Equity Round | 0 |
| 4/2011 | Eiger BioPharmaceuticals | Series A | 14.5M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 6/2010 | Vicept Therapeutics | Series A | 16M |
| 7/2018 | Sinovac Biotech | Post-IPO Equity | 86.7M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 2/2021 | Innocare | Post-IPO Equity | - |
| 9/2018 | AirXpanders | Post-IPO Equity | 15M |
| 4/2012 | AirXpanders | Series D | 11M |
| 1/2012 | AirXpanders | Series D | 10.3M |
| 1/2021 | Serán Bioscience | Venture Round | - |
| 9/2014 | AirXpanders | Series E | 1M |
| 3/2023 | EpiBiologics | Series A | 0 |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 4/2018 | Poseida Therapeutics | Series B | 0 |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 10/2014 | Aclaris Therapeutics | Series B | 21M |
| 1/2000 | Med-eCommerce.com | Venture Round | 2M |
| 11/2002 | Copernicus Therapeutics | Venture Round | 2M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 1/2005 | NextWave Pharmaceuticals | Series A | 10M |
| 7/2015 | Gengmei | Series B | - |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 5/2021 | Scientia Vascular | Private Equity Round | 50M |
| 2/2021 | ASLAN Pharmaceuticals | Post-IPO Equity | 18M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 2/2018 | Innocare | Private Equity Round | 55M |
| 2/2003 | AgraQuest | Venture Round | 9.4M |
| 11/2011 | Medley Health | Series A | 20M |
| 8/2017 | Amyris | Post-IPO Equity | 50M |
| 6/2018 | Cerebral Therapeutics | Series A | 3M |
| 9/2007 | Sagent Pharmaceuticals | Series A | 53M |
| 7/2022 | Tebra | Series B | 0 |
| 1/2015 | Synapse Biomedical | Venture Round | - |
| 9/2008 | Sagent Pharmaceuticals | Series A | 30M |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 8/2008 | InteKrin | Series C | 0 |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 11/2017 | OMNI | Series C | - |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 12/2022 | Ronovo Surgical | Series B | - |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 6/2017 | Platelet BioGenesis | Series A | 0 |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 11/2019 | Genetron Health | Series D | 71M |
| 1/2007 | InteKrin | Series B | 0 |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 7/2016 | Tricida | Series C | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 12/2004 | Prestwick Pharmaceuticals | Series B | 37M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 6/2013 | AirXpanders | Series E | 9M |
| 4/2021 | Sera Prognostics | Series E | 0 |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 9/2019 | Passage Bio | Series B | 110M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 9/2021 | Attralus | Series B | 116M |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 6/2012 | SentreHEART | Series C | 26M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 11/2017 | Tricida | Series D | 0 |
| 5/2021 | Aerobiotix | Venture Round | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 1/2010 | Neomend | Series D | 30M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 2/2009 | Eiger BioPharmaceuticals | Series A | 8.3M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 6/2009 | Sagent | Series A | 30M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 6/2003 | Prestwick Pharmaceuticals | Series A | 15M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 8/2020 | PatientPop | Series C | 50M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 4/2021 | Ronovo Surgical | Series A | - |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 2/2007 | NextWave Pharmaceuticals | Series B | 40M |
| 8/2007 | Prestwick Pharmaceuticals | Venture Round | 20M |
| 3/2019 | Cerebral Therapeutics | Series A | 7.8M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 3/2019 | MacuLogix | Series D | 0 |
| 3/2021 | Ossium Health | Series B | 63M |
| 6/2018 | Metacrine | Series C | 65M |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 9/2016 | ReadCoor | Series A | 23M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 9/2018 | Immune-Onc Therapeutics | Series B | 33M |
| 11/2018 | Visen Pharmaceuticals | Series A | 0 |
| 10/2006 | Prestwick Pharmaceuticals | Series C | 60M |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 5/2004 | CAPNIA | Series B | 12M |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 12/2022 | Pulmocide | Series C | 0 |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 11/2017 | Medeor Therapeutics | Series B | 0 |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 10/2012 | Aclaris Therapeutics | Series A | 21M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2016 | SentreHEART | Series D | 35M |
| 6/2021 | RayzeBio | Series C | 108M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 5/2017 | Aadi | Series A | 23M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 11/2022 | Bonum | Series A | 93M |
| 2/2019 | Bolt | Series B | 54M |
| 11/2004 | ViOptix | Series C | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 3/2017 | Angiotech Pharmaceuticals | Venture Round | - |
| 10/2019 | INBRACE | Series C | 45M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 3/2021 | OMNI | Series D | - |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 9/2017 | Kadmon | Post-IPO Equity | 80.4M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
